Quick Facts: Folltropin V

• Target Population: Reproductively mature heifers and cows.
• Therapeutic Domain: Reproductive management in beef and dairy cattle.
• Main Goal: Facilitating the induction of superovulation.

---

Folltropin V is an approved veterinary medication used as part of established reproductive management protocols in beef and dairy cattle. The primary purpose of this agent is to assist veterinarians and producers in inducing superovulation in reproductively mature heifers and cows.

Superovulation is a critical process for certain reproductive technologies, such as embryo transfer. The drug is intended to promote the development of multiple ovarian follicles in the target animal during a specific phase of the estrous cycle, a necessary step to potentially obtain a higher number of ova or embryos. This action is supported by its follicle-stimulating properties.

The use of this agent is a valuable element in protocols designed to optimize embryo collection efforts. Successful application of this regimen often relies on the general reproductive health of the animal and adherence to comprehensive herd management procedures. The prescribing veterinarian will determine its appropriate use within a complete breeding strategy.

Who Can and Cannot Use Folltropin V?

The eligibility for Folltropin V is strictly defined by regulatory documents, limiting its use to a precise population within the bovine species (cattle).

---

Eligibility Scope

Classification	Eligible Population	Contraindicated Population
Species/Sex	Reproductively mature cows and heifers	Male cattle (Bulls)
Maturity	Reproductively mature female cattle	Reproductively immature heifers
Physiological State	Lactating dairy cows (Use permitted)	Pregnant cattle (Absolute Contraindication)

---

Condition-Based Restrictions

The medicine is contraindicated for use in animals with known hypersensitivity to the active ingredient, Urofollitropin, or any other component of the formulation.

Regulatory authorization restricts use to clinically healthy and normally cycling cows and mature heifers. This means eligibility is dependent upon the animal possessing good general and reproductive health, as established in the official prescribing information.

Folltropin V Interactions with Other Medicines and Products

Folltropin V’s interaction profile is primarily defined by the absence of known drug-drug interactions, alongside specific mandatory requirements for the superovulation protocol.

Drug-Drug and Metabolic Interactions

Official regulatory documents do not formally list any known interactions between Folltropin V (Urofollitropin) and other veterinary medicinal products that alter systemic drug exposure. Interactions involving metabolic pathways, such as cytochrome P450 (CYP) enzymes, or drug transporters like P-glycoprotein, are not documented in the product labeling. Therefore, no contraindicated combinations are listed based on conventional pharmacokinetic or pharmacodynamic interaction risk.

Mandatory Pharmacodynamic Co-administration

The treatment regimen includes a critical pharmacodynamic requirement: the mandatory co-administration of an approved prostaglandin product, such as cloprostenol sodium or dinoprost tromethamine. This is not a drug interaction that modifies clearance but a necessary component of the overall superovulation protocol. The official timing rule dictates that the prostaglandin must be administered in conjunction with the sixth dose of Folltropin V.

Physical Incompatibility Restriction

Regulatory labels specify a physical incompatibility rule that prohibits mixing the lyophilized powder with any substance other than the supplied sterile diluent prior to injection. The product labeling contains no documentation regarding interactions with food, supplements, or herbal products.

Folltropin V is a highly purified form of porcine follicle-stimulating hormone (pFSH). It is a glycoprotein that acts as an agonist by binding to the follicle-stimulating hormone receptors (FSHR) on ovarian granulosa cells. This binding initiates intracellular signaling cascades, primarily through the adenylyl cyclase/cyclic AMP (cAMP) pathway, modulating gene expression related to cellular proliferation and differentiation in the ovary.

The activation of FSHR by pFSH leads to the upregulation of aromatase activity and the increased synthesis of estrogens and inhibins. The subsequent production of these hormones exerts negative feedback on the hypothalamic-pituitary axis. The pFSH molecule primarily targets the FSHR, with minimal activity toward the luteinizing hormone receptor (LHR). FSHR activation is followed by the expression of LHR on the dominant follicle, regulating the final steps of follicular development.

How Folltropin V is Used: Administration Guidelines

The usage of Folltropin V is defined by a precise protocol within veterinary reproductive management, which is restricted to use by or on the order of a licensed veterinarian. This medicine is supplied as a lyophilized powder that requires reconstitution using 20 mL of the supplied sterile diluent under strict aseptic technique. The resulting solution is intended for intramuscular (IM) injection into deep muscle tissue, as injection into subcutaneous tissue is not effective.

---

Dosing and Schedule

The standard superovulation regimen calls for a total cumulative dose of 700 IU of FSH (Follicle-Stimulating Hormone) administered over a four-day period. This total dose is divided into 8 separate injections, each consisting of 2.5 mL of the reconstituted solution (87.5 IU FSH), and must be administered twice daily at precise 12-hour intervals.

Cycle Timing and Protocol

The 4-day injection course is initiated on Day 8 to 10 of the estrous cycle in reproductively mature heifers and cows. The protocol includes the co-administration of a prostaglandin product, which is timed to coincide with the 6th injection of Folltropin V. These parameters establish the standardized, time-bound procedural framework necessary for the use of the product.

Research Evidence / Overview of Studies for Folltropin V

Evidence for Use in Controlled Follicular Stimulation (Superovulation)

The primary research for Folltropin V has been studied for its application in inducing superovulation, a process studied for the possibility of obtaining a higher number of ova or embryos. Research has extensively examined the medicine in this context. These studies include Randomized Controlled Trials (RCTs) and Controlled Field Efficacy Studies, which are considered high-quality research designs and were submitted to regulators as part of the evaluation process for the approved indication. These trials compared the standard Folltropin V protocol against alternative treatment schedules or other gonadotropin treatments.

In these studies, researchers observed the patterns of ovarian activity, including the number of developed follicles and ovulations (Corpora Lutea). They also measured the resulting outcomes related to embryo recovery metrics, such as the total number of ova and embryos collected. Studies also explored the relationship between different doses and these recovery metrics. Findings from this research describe how outcomes are highly sensitive to external variables and individual biological differences.

Evidence in Specific Bovine Populations

Research studies have explored the use of Folltropin V across various reproductively mature bovine populations. This includes controlled trials that evaluated the superovulatory response in both beef cattle and dairy cattle to assess if different physiological groups exhibited similar patterns. These findings describe the patterns observed in the studies but highlight that results apply only to the specific populations that were studied.

What Remains Uncertain in the Research

While a body of research has been conducted, certain areas of uncertainty remain in the broader evidence landscape. One key research limitation frame is the widely noted biological heterogeneity—the results showed high natural variability in superovulatory response between individual animals, making generalized predictions challenging. Additionally, studies exploring dose-response patterns have, at times, provided mixed findings that require further context.

Key Studies & References

1. FOLLTROPIN® [porcine pituitary-derived follicle stimulating hormone for injection] - DailyMed (FDA-Approved Labeling)
2. Curtailing the conventional dose of Folltropin-V for superstimulation and embryo recovery in Sahiwal cattle (Bos indicus)

Common questions about Folltropin V (FAQ)

---

Q: How long does Folltropin V stay active in the body?

A: According to official product information, the active ingredient in Folltropin V, Follicle-Stimulating Hormone (FSH), has a relatively short half-life of approximately five hours after injection. This means the concentration of the hormone in the body decreases quickly. This short duration is a consideration for the twice-daily administration protocol described in official documents.

---

Q: Is Folltropin V the same as Folltropin (without the V)?

A: Folltropin and Folltropin V are both brand names used to describe the porcine pituitary-derived follicle-stimulating hormone (FSH) used for superovulation. Regulatory labels typically treat the products as functionally equivalent, with the same core indication and protocol. Minor differences may relate to country-specific packaging or minor variations in inactive ingredients.

---

Q: Are there any specific food or drinks that should be avoided while using Folltropin V?

A: Official regulatory documents and product labels do not contain any documentation regarding interactions between Folltropin V and food, supplements, or herbal products. This indicates that no specific dietary restrictions are formally listed in the official prescribing information.

---

Q: What does 'folltropin' mean in a medical context?

A: In a medical context, 'Follitropin' is the established name for the active substance that acts as the Follicle-Stimulating Hormone (FSH) component. FSH is a natural glycoprotein hormone that controls the growth of follicles, which are small sacs in the ovary that contain an egg.

---

Q: Can Folltropin V affect the results of standard blood tests?

A: Studies and official information indicate that the superovulation protocol, which includes Folltropin V, is expected to cause changes in the concentration of circulating hormones in the body, such as estradiol. It is known that the treatment itself is intended to alter these reproductive hormone levels, but no specific information is provided on interference with non-hormone-related standard blood tests.

---

Q: Is Folltropin V a scheduled or controlled substance?

A: Folltropin V is not classified as a controlled substance by the DEA (Drug Enforcement Administration) in the United States. However, official federal law restricts this drug to use by or on the order of a licensed veterinarian, indicating its status as a veterinary prescription-only medicine.

---

Q: Why might a healthcare professional choose Folltropin V for a patient?

A: Official discussion frames often highlight that the purification process used to create Folltropin V ensures a consistently low ratio of luteinizing hormone (LH) to FSH. This specific purity profile is a factor recognized in research as supporting the goals of the superovulation protocol.

---

Q: Is Folltropin V associated with any long-term chronic conditions?

A: Official safety reviews conclude that the existing pharmacology and toxicology information was considered sufficient to demonstrate the medicine is not systemically toxic to the animal. Furthermore, research examining repeated superovulation protocols did not show adverse effects on the subsequent quality of the reproductive outcome.

---

Q: Why are there different strengths or presentations of Folltropin V?

A: Folltropin V is supplied in different presentations, such as a Kit (containing one powder vial and one diluent vial) and a Dual Pack (containing two powder vials). These variations provide flexibility depending on the professional need, such as the total dosage required or the availability of the required diluent.

---

Q: Does Folltropin V have any non-hormonal components?

A: The active ingredient (FSH powder) vial itself contains no inactive ingredients. However, the supplied sterile diluent—which is used to reconstitute the powder—does contain non-hormonal components, including Sodium Chloride and Benzyl Alcohol, along with water for injection.

---

Q: How quickly can someone expect to see research-related changes after starting Folltropin V?

A: The entire Folltropin V protocol is designed as a four-day injection course because the effect of follicular growth is driven by the daily administered hormone. The protocol is timed to be initiated at a specific time in the estrous cycle, following the natural patterns of follicular growth.

---

Q: Is it normal to feel a mild burning sensation at the injection site for Folltropin V?

A: Regulatory documents state that it is possible to experience localized reactions at the injection site, such as general irritation or swelling. While a specific 'burning' sensation is not explicitly named, it falls under the category of expected localized discomfort or irritation.

---

Q: What is the function of the inactive ingredients in Folltropin V?

A: The primary function of the inactive components within the diluent, such as Bacteriostatic Sodium Chloride Injection USP, is to serve as the vehicle for the medicine. They also play a role in maintaining the stability and sterility of the multi-dose solution once it has been prepared for administration.

---

Q: Does the time of day matter for using Folltropin V?

A: Yes, the official dosing instructions state that the standard protocol requires administration twice daily at precise 12-hour intervals over the four-day period. This precise timing is an established requirement of the standard controlled superovulation protocol.

How to Store and Dispose of Folltropin V?

Folltropin V has distinct storage requirements before and after mixing.

Storage Conditions

Product Form	Temperature Range	Protection Requirement
Unreconstituted (Powder/Diluent)	Store at or below 25°C (77°F)	Keep vials in the outer carton to protect from light
Reconstituted Solution	Store refrigerated at 2°C–8°C (36°F–46°F)	Must not be frozen

Unopened vials have a shelf-life of up to 4 years. The reconstituted solution must be used or discarded within 4 to 5 days. Before use, strict aseptic technique is required for preparation, and the solution must be checked for particulates. Keep this medicine out of the sight and reach of children.

Disposal Instructions

Discard any unused reconstituted portion. The product should not be disposed of via wastewater or household waste. Follow local, state, and national regulations, or use an official drug take-back scheme for proper disposal of unused medicine and sharps.